FDA starts tracking site

Koroneos, George
October 2008
Pharmaceutical Representative;Oct2008, Vol. 38 Issue 10, p9
The article reports on the quarterly listing of drugs publicly post by the Food and Drug Administration (FDA) as required by the Food and Drug Administration Amendments Act of 2007 in the U.S. A total of 20 drugs have been listed in the first round of list published in September 2008 which include Eli Lilly and Co.'s Cymbalta, Biogen Idec Inc.'s Tysabri and Purdue's Oxycontin. The list aims to improve the transparency of drugs and identify its potential safety issue.


Related Articles

  • Merck, Biogen, Lilly Top 2016 Drug Approvals Despite FDA Slump. GATLIN, ALLISON // Investors Business Daily;1/19/2017, p25 

    The article reports that the U.S. Food and Drug Administration's (FDA) drug approval rate has declined in 2016. Topics discussed include a major increase of oncology drugs on the FDA approval list, the agency's increased appetite for drugs to treat diabetes, and information on new drugs...

  • FDA Actions.  // Neurology Alert;Nov2007, Vol. 26 Issue 3, p2 

    The article deals with several drug approvals from the U.S. Food and Drug Administration (FDA) as of November 2007. An approval to market raloxifene for the indication of reducing the risk of breast cancer in postmenopausal women who are at high risk for invasive breast cancer has been received...

  • Lilly Icos completes US regulatory submission for Cialis.  // PharmaWatch: CNS;August 2003, Vol. 2 Issue 8, p26 

    Reports on the submission of the additional data requested by the U.S. Food and Drug Administration (FDA) related to the Cialis anti-impotence drug manufactured by Lilly Icos LLC in the U.S. Acceptance of the requirement by the FDA; Expectation of the company for a final regulatory decision on...

  • Lilly warned over Alimta patient booklet. M. A. // Medical Marketing & Media;Sep2006, Vol. 41 Issue 9, p28 

    The article reports on the United States Food and Drug Administration's issuance of a warning letter to Eli Lilly over a patient brochure for its oncology treatment Alimta. According to the Division of Drug Marketing, Advertising and Communications, the letter is misleading because it fails to...

  • Genentech/Biogen Idec: Rituxan further expands its options.  // PharmaWatch: Monthly Review;Apr2006, Vol. 5 Issue 4, p29 

    The article reports that the U.S. Food and Drug Administration approved the drug Rituxan from Genentech Inc. and Biogen Idec Inc. to help treat rheumatoid arthritis (RA). The approval allows the companies to market Rituxan to be used with methotrexate for the treatment of signs and symptoms of...

  • FDA to Lilly: Can Cymbalta journal ads. M. A. // Medical Marketing & Media;Dec2005, Vol. 40 Issue 12, p11 

    The article reports that the U.S. Food and Drug Administration has called on pharmaceutical company Eli Lilly & Co. to stop journal advertisements for Cymbalta as a treatment for nerve pain caused by diabetes as they fail to address drug risks. According to the Division of Drug Marketing,...

  • FDA/EMA ROUNDUP.  // MondayMorning;11/ 5/2012, Vol. 20 Issue 42, p1 

    The article offers U.S.-based pharmaceutical industry news brief as of November 5, 2012. The U.S. Food and Drug Administration (FDA) have delayed the decision regarding drugs and medical devices due to the sandy storm. The shares of BioCryst Pharmaceuticals Inc. have dropped after its withdrawal...

  • Biogen Idec and Elan Receive Notification of PDUFA Date Extension.  // Biomedical Market Newsletter;10/26/2011, Vol. 21, p606 

    The article reports on the extension given to Biogen Idec Inc. and Elan Corp. PLC by the U.S. Food and Drug Administration (FDA) for their initial Prescription Drug User Fee Act (PDUFA) date involving the review of their co-marketed supplemental Biologics License Application (sBLA) for TYSABRI....

  • Washington report. Dickinson, James G. // Medical Marketing & Media;Dec98, Vol. 33 Issue 12, p26 

    Presents news briefs from the pharmaceutical industry in the United States (US) in 1998. Plans of Eli Lilly company after receiving US Food and Drug Administration (FDA) non-approval letter for its schizophrenia treatment Zyprexa; Why the General Accounting Office has been asked to investigate...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics